A drug combo cleared liver scarring in 47% of patients — placebo managed 7%
Senescent cells — the damaged, zombie-like cells that refuse to die — have long been a target in aging research.
This week, a small but striking clinical trial tested whether clearing them out could actually reverse liver scarring in humans.
🧫 Zombie Cell Killers Just Passed a Human Liver Test
- 31 people with fibrotic liver disease (a condition where scar tissue builds up and current drugs often stall) were randomized to receive dasatinib plus quercetin — a cancer drug paired with a plant compound — or placebo, three days a week over roughly five months.
- The result: 47% of the treated group showed meaningful fibrosis improvement without disease worsening, versus 7% on placebo. Full disease resolution happened in 53% of treated patients versus 7% on placebo. Single-cell sequencing confirmed the drug combo actually reduced senescent and scar-forming cell populations in liver tissue.
- The catch: adverse events hit 82% of the treated group versus 43% on placebo — though all were self-limiting. This was a 31-person proof-of-principle trial, not a definitive answer.
Why it matters: This is one of the first randomized controlled trials to show senolytics — drugs that selectively clear senescent cells — can move a hard clinical endpoint in humans, not just in mice.
Key Findings
🤖 A Neural Net Can Read Stem Cell Aging From a Microscope Image
- Researchers trained a deep learning model called ChromAgeNet on 3D images of DNA-stained blood stem cell nuclei to distinguish young from old mouse cells — hitting an accuracy score of 0.77, outperforming classical models built on handcrafted features.
- The model flagged chromatin entropy, peripheral heterochromatin, and chromatin condensates as the key aging signals, and showed early promise as a drug screening tool for rejuvenation compounds.
📊 Organ 'Age Clocks' Are Useful — But Brain and Lungs Beat Them
- A 16-year mortality study of 861 older adults benchmarked protein-based organ aging clocks against established biomarkers. Accelerated liver, immune, and heart aging were the strongest proteomic predictors of death.
- But epigenetic age, brain volume, respiratory function, and cognition all showed stronger associations with mortality than any organ clock — a reminder that proteomics is powerful but not yet king.
🚫 Autophagy Doesn't Simply Decline With Age — It Gets Complicated
- A human aging study tracking autophagy activity across multiple matched cell types found the picture is messier than the textbook version: flux decreased in male skin cells with age, stayed stable in female skin cells, and actually increased in female neurons.
- In adults over 70, higher autophagy activity was linked to worse physical function — suggesting elevated flux in late life may reflect stress response, not enhanced cellular housekeeping.
💉 A Safer 'Senescent Cell Assassin' Works in Monkeys
- CAR-T cells that hunt senescent cells have shown toxicity problems in prior work. A new bispecific T-cell engager (a more dose-controllable immune tool) targeting the same surface marker cleared senescent cells and reduced age-related pathologies in both aged mice and non-human primates.
- The key: liver enzyme monitoring guided dosing, keeping toxicity in check. Low-dose treatment worked without adverse effects when transaminase levels were tracked.
🔬 Blocking a Calcium Buildup Slows Lung Scarring in Mice
- Senescent lung fibroblasts accumulate excess intracellular calcium, and that buildup appears to drive reactive oxygen species, DNA damage, and the inflammatory signals that worsen pulmonary fibrosis.
- In mice, injecting a calcium chelator markedly reduced fibrosis markers, collagen deposits, and inflammatory cell infiltration — and suppressed the secretory signals that senescent cells normally broadcast to neighboring tissue.
Implications
Senolytics just cleared a meaningful human hurdle in liver disease, but the 82% adverse event rate in a 31-person trial leaves a real question open: can the therapeutic window be widened enough for broader use, or will toxicity remain the ceiling that animal models never warned us about?
Studies in this issue
Primary sources used for this newsletter.
- Senolytic drugs dasatinib and quercetin in fatty liver disease linked to metabolism: a first controlled trialmain storyNature metabolism2026-10-01PMID 42823536
- Multiple Age-Related Health Markers and Blood Protein Patterns Linked to Risk of Deathkey findingAging cell2026-10-02PMID 42823846
- Changes in Cell Recycling Activity with Age Differ Between Sexes and Cell Types and Relate to Lower Physical Ability in Older Adultskey findingAging cell2026-09-28PMID 42802483
- Reducing calcium buildup inside cells may ease cell aging and lung scarringkey findingBiochimica et biophysica acta. General subjects2026-09-30PMID 42815787
- Using Deep Learning to Predict Blood Stem Cell Aging from 3D DNA Structure Imageskey findingAging cell2026-09-28PMID 42802377
- T Cells Targeting uPAR Remove Aged Cells in Mice and Primates with Liver Enzyme Levels Used to Monitor Safetykey findingAging cell2026-09-29PMID 42806572
Continue reading
All Longevity & Aging issuesGet the next Longevity & Aging issue
Seven papers, once a week. Free.